Elutia Regains Full Nasdaq Compliance, Averting Delisting Risk
ELUT has more than doubled off its 52-week low of $0.5 on light trading volume (0.2× avg).
Summary
Elutia Inc. announced it has regained full compliance with Nasdaq's minimum bid price and market value requirements, resolving previous non-compliance notices and securing its listing.
Key Events · Corporate Governance and Compliance · ELUT
-
Regained Minimum Bid Price Compliance
On March 2, 2026, Nasdaq notified Elutia that it had regained compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)), having maintained a closing bid price of $1.00 or greater for 10 consecutive business days.
-
Regained Minimum Market Value Compliance
On February 5, 2026, Nasdaq notified Elutia that it had regained compliance with the Minimum Market Value of Listed Securities (MVLS) Requirement (Rule 5550(b)(2)), with its MVLS being $35 million or greater for 11 consecutive business days.
-
Nasdaq Matters Closed
As a result of regaining compliance with both requirements, Nasdaq has confirmed that these matters are now closed, and the company is in full compliance with all continued listing requirements.
Analysis · ELUT · Life Sciences
Elutia Inc. has successfully regained compliance with both Nasdaq's minimum bid price and minimum market value of listed securities requirements. This is a significant positive development for the company, as it removes the immediate threat of delisting that had been an overhang since late 2025. Maintaining a Nasdaq listing is crucial for liquidity, investor confidence, and access to capital for a company of Elutia's size. The CFO's statement highlights the company's belief that this reflects investor confidence in their technology and market opportunity.
At the time of this filing, ELUT was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.1M. The 52-week trading range was $0.50 to $3.46. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.